Pharmacy Articles

Pharmacy

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Stoch SA et al. - These studies showed ODN to be well tolerated. Pharmacokinetic analysis revealed a long half-life consistent with once-weekly dosing. Pronounced reductions in C-terminal telopeptide of type I collagen and N-terminal telopeptide of type I collagen normalized to creatinine at trough were seen following weekly administration. Robust reductions in CTx and NTx/Cr were seen following daily administration. ODN exhibits robust and sustained suppression of bone resorption biomarkers at weekly doses >= 25 mg and daily doses >= 2.5 mg.

Today in Other Drugs...keeping you current

Meta-analysis of the evidence for a partially hydrolyzed 100% whey formula for the prevention of allergic diseases
Current Medical Research and Opinion, 12/18/09

Vardenafil for the treatment of erectile dysfunction: an overview of the clinical evidence
Clinical Interventions in Aging, 12/18/09

Iron supplementation in the non-dialysis chronic kidney disease patient: oral or intravenous
Current Medical Research and Opinion, 12/18/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address